Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02567370 · ClinicalTrials.gov registry record · Phase 1
Single-ascending Dose Study With a Food-Effect Cohort to Evaluate AMG 581
A Phase 1 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 1
- Development phase
- 70
- Enrollment target
NCT02567370 is a Phase 1 study that has completed, run by Amgen. The registered enrollment target is 70 participants.
The verdict
NCT02567370, a Phase 1 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 70 participants
- Enrollment target
Study Summary
The purpose of this study is to find out the time it takes to absorb, distribute, breakdown and remove the drug from the body, safety and tolerability of AMG 581 in healthy participants and subjects with schizophrenia.
Interventions
- DRUG Placebo
- DRUG AMG 581
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2015-08 |
| Est. Completion | 2015-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02567370
The ClinicalTrials.gov registry entry for NCT02567370 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02567370 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02567370 about?
NCT02567370 is a clinical study titled "Single-ascending Dose Study With a Food-Effect Cohort to Evaluate AMG 581". The purpose of this study is to find out the time it takes to absorb, distribute, breakdown and remove the drug from the body, safety and tolerability of AMG 581 in healthy participants and subjects with schizophrenia.
What is the current status of trial NCT02567370?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 70 participants. The study started on 2015-08. Estimated completion is 2015-10.
What interventions are being tested in trial NCT02567370?
The interventions under investigation include: Placebo (DRUG), AMG 581 (DRUG).
Who is sponsoring clinical trial NCT02567370?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.